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E-mail address: ssala@umh.es (S. Sala).We have studied the role of the highly conserved residue aLysine145 in the early steps of activation
by acetylcholine of the nicotinic acetylcholine receptor (nAChR). Both macroscopic and single-chan-
nel currents were recorded in the slowly desensitizing chimeric mutant receptor a7V201-5HT3A/
R432Q/R436D/R440A, made of a7 nAChRs and serotonin receptors of subtype 3A (ch1), and its cor-
responding mutant K145A (ch1/K145A) expressed in Xenopus oocytes. Mutant ch1/K145A receptors
had a reduced gating function similar to that produced by the same mutation in the wild type recep-
tor a7. The mutated receptor has reduced opening rate constants, b, and increased closing rate
constants, a.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Nicotinic acetylcholine receptors (nAChRs) mediate fast synap-
tic transmission in muscle and nerve cells. They are members of
the Cys-loop family of ligand-gated ion channels, which includes
5-hydroxytryptamine3 (5-HT3) receptors, gamma-aminobutyric
acid (c-GABAA) receptors, and glycine receptors [1].
In a previous work [2] we determined the inﬂuence of the
highly conserved residue Lysine145 in a7 receptors upon binding
and gating by using measurements of macroscopic currents and
binding of alpha-bungarotoxin (a-Bgt). The role of the same resi-
due was also studied at the single-channel level in muscle recep-
tors [3,4] where it was found that the mutation K145A produced
a large reduction in the opening rate constant.
We also tried to study the role of K145 at the single-channel le-
vel in a7 receptors but the fast desensitization of the wild type
receptor makes very difﬁcult to obtain single-channel data, so we
tried to use instead a mutated receptor slowly desensitizing and
makes easier the task of obtaining long duration single-channel
recordings.chemical Societies. Published by E
eceptors; 5-HT3, 5-hydroxy-
a-Bgt, alpha-bungarotoxin;
aconitine; DHbE, dihydro-b-In a recent work [5] we used the mutant a7L248T as our model
receptor because it has very slow desensitization and it was possi-
ble to record single-channel currents in steady state conditions.
Thus, we were able to study the effect of mutation K145A at the
single-channel level. However, the mutant a7L248T was not a good
model in other respects because it behaved differently than the
wild type receptor when the pharmacology of the mutated recep-
tor was studied. In particular, the mutation K145A in wild type a7
receptors produces a receptor that is inhibited by the agonist
dimethylphenylpiperazinium (DMPP). On the contrary, the same
mutation on a7L248T gives a receptor that is activated by DMPP,
thus the mutation did not produce the alteration of pharmacology
expected.
We decided to pursue further the research of the mutation
K145F at the single-channel level by testing another construct that
allowed us the recording of microscopic currents in stationary con-
ditions. So we used the chimera receptor a7V201-5HT3A/R432Q/
R436D/R440A as our model (referred as ‘‘ch1” hereafter). This chi-
mera is constructed of a7 from the N-terminus up to the position
Val201 and the rest is made of serotonine (5-HT3A) receptor [6].
In addition, the three arginine mutations within the large cytoplas-
mic loop of the receptor result in a mutant channel with a conduc-
tance large enough to be recorded directly [7].
The recording of whole-cell macroscopic currents revealed that
the mutation ch1/K145A produced a receptor with the same phar-
macology that the original a7/K145A mutant receptor, thus in this
respect ch1/K145A constitutes a better model to pursue the studylsevier B.V. All rights reserved.
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2.1. Generation of mutants of the bovine a7 subunit
The bovine a7 cDNA was cloned in a derivative of the pSP64T
vector [8] containing part of the pBluescript polylinker. To generate
the mutants we annealed single-stranded oligonucleotides with
the desired sequences and proper single-strand ends that could
be easily ligated to the ends generated through restriction enzymes
digestion of the a7 and/or the 5-HT3A receptor cDNAs. The restric-
tion enzyme sites for cloning the annealed oligonucleotides were
either present in the original cDNA sequences or introduced as si-
lent mutations [9] by using mutated oligonucleotides and PCR (25
cycles at 94 C for 10 s, 60 C for 30 s and 72 C for 45 s).
2.2. Oocyte expression
Capped mRNAwas synthesized in vitro using SP6 RNA polymer-
ase, the mMESSAGEmMACHINE kit (Ambion, Texas) and the
pSP64T derivative mentioned above. Defoliculated Xenopus laevis
oocytes were injected with 550 lg/ll of total cRNA in 50 nl of ster-
ile water. Oocytes were incubated in calcium-free medium. All
experiments were performed within 3–4 days after cRNA injection.
2.3. 125I-a-bungarotoxin binding assays
Speciﬁc surface expression of 125I-a-bungarotoxin (125I -a-Bgt)
binding sites was tested with 10 nM 125I-a-Bgt as described [10].
Brieﬂy, oocytes located in 24-well plates were preincubated for
15 min with Barth’s buffer containing 5% of fetal calf serum and
further incubated in the same medium with 10 nM 125I-a-Bgt for
2 h at 18 C in a ﬁnal volume of 300 ll. At the end of the incuba-
tion, unbound 125I-a-Bgt was removed, oocytes were passed to
six-well plates, washed ﬁve times with 4 ml Barth’s buffer and
bound radioactivity was counted. Non-speciﬁc binding was deter-
mined using uninjected oocytes.
2.4. Macroscopic whole-cell recordings
Electrophysiological recordings of whole-cell currents were
done as described previously [10]. The extracellular solution con-
tained (in mM): NaCl 82.5, KCl 2.5, BaCl2 2.5, MgCl2 1 and HEPES
5 (pH 7.4). The velocity of application of agonists was 18–22 ml/
min. All experiments were done at room temperature (22 C). Un-
less otherwise indicated, oocyte membrane potential was held at
40 mV. Macroscopic currents were measured with the Clampﬁt
9 (Molecular Devices) software. Data points are shown as means
with standard errors. Data analysis was performed with Prism
4.0 (GraphPad Software Inc., San Diego, CA, USA). Current–concen-
tration curves were ﬁtted using a non-linear least squares algo-
rithm to the Hill equation, I/Imax = 1/(1 + (EC50/C)n), were EC50 is
the agonist concentration that elicits the half-maximal response,
n is the Hill coefﬁcient, and C is the agonist concentration. Afﬁnity
constants were calculated by a modiﬁed Cheng–Prusoff equation
[11] .
2.5. Single-channel recordings
Single-channel records were obtained in the cell-attached mode
using an Axopatch 200A ampliﬁer (Axon Instruments, CA). Oocytes
were bathed in a modiﬁed extracellular solution where NaCl was
substituted by KCl to clamp the membrane potential close to0 mV. Holding potential of the patch was 100 mV. Patch pipettes
were pulled from thick-walled borosilicate glass (GC150-15, Clark
Electromedical Instruments), with a resistance between 5 and
10 MX when ﬁlled with standard extracellular solution. ACh or
DMPP were added to the pipette solution. Records were low-pass
ﬁltered at 1 kHz with an 8-pole Bessel ﬁlter (Frequency Devices
Inc.), sampled at 20 kHz and stored on hard disk for later analysis.
Single-channel recordings were analyzed with the Clampﬁt 9
and the QUB-1.4.0.2 software suite [12]. For each patch a voltage
pulse protocol was applied to determine the conductance (c) and
reversal potential (Vr) of the channels. Ten second duration pulses
were applied from +60 to 120 mV at 20 mV intervals. Single-
channel current–voltage curves were ﬁtted to the equation
I = c(V  Vr). Open probabilities were estimated from all point his-
tograms ﬁtted to a sum of Gaussians.
Kinetic analysis was performed on records with a dead time of
0.1 ms, idealized by the half amplitude threshold method, and re-
stricted to bursts of activity of a single-channel. Bursts were iden-
tiﬁed by a closed interval longer than a given critical time that
usually was between 30 and 100 ms, and containing more than
three opening events. The selected region of the idealized data
was then ﬁtted to a simple kinetic model with three closed and
two open states, with eight kinetic constants, as shown in kinetic
Scheme 1, with the MIL method that gives directly an estimate of
the kinetic constants and their standard errors. This scheme has
been used here because it has the minimum number of states
needed to ﬁt the open and closed dwell time histograms. Dwell
time histograms with the corresponding time constants, and their
relative weight, were also obtained with the same program. Statis-
tical analysis of the ﬁtted parameters and t-tests for the signiﬁ-
cance of the difference between two sample means were
performed with SPSS14 (SPSS Inc.).
3. Results
3.1. Effect of the mutation K145A on the functional responses to ACh in
the slowly desensitizing chimera receptor ch1
Fig. 1A shows two families of macroscopic inward ACh-evoked
currents in chimeric ch1 and mutant ch1/K145A receptors, respec-
tively. Inward currents evoked at equivalent ACh concentrations
had the same kinetics both in ch1 and mutant ch1/K145A recep-
tors. In average, maximal currents in mutant ch1/K145A were
around 9-fold smaller than in control despite the fact that the elec-
tromotive force was 2-fold larger, and surface expression, as mea-
sured by a-Bgt binding, was similar in both cases (ch1 and mutant
oocytes expressed 31 ± 3 and 35 ± 3 fmol/oocyte of a-Bgt, respec-
tively). Thus, after normalizing functional responses to surface
expression and taking into account the difference in electromotive
force, mutant ch1/K145A showed a gating function (current to
binding ratio) of approximately 8% of control. This reduction in gat-
ing is larger than that obtained after the inclusion of the same
mutation in wild type a7 receptors [2]. On the other hand, as
shown in Fig. 1B, mutant ch1/K145A had a decrease in ACh potency
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Fig. 1. A comparison between the ACh responses of chimera ch1 and mutant ch1/
K145A. (A) Inward currents obtained upon stimulation with ACh of ch1 and ch1/
K145A mutants. Traces represent currents obtained at 40 mV with ACh concen-
trations from 3 to 3000 lM in ch1 and at 80 mV with ACh concentrations from 30
up to 30000 lM for the mutant ch1/K145A. The bar over the traces indicates the
period of 4 s during which the ACh was applied. (B) ACh maximal current–
concentration curves of single oocytes expressing ch1 receptors (open circles) and
K145A mutants (solid circles) for the maximal currents shown in (A). Lines
represent ﬁts to the Hill equation. ch1: Imax = 9.2 ± 0.1 lA, EC50 = 46 ± 2 lM and
nH = 2.9 ± 0.2. Mutant ch1/K145A: Imax = 1.62 ± 0.01 lA, EC50 = 2780 ± 35 lM,
n = 2.2 ± 0.1. These particular oocytes were chosen because the results of the
individual ﬁt parameters were close to the average values (Table 1 in Supplemen-
tary data), although their desensitizing kinetics is slower than average.
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Fig. 2. Pharmacological proﬁle: agonists. Current–concentration curves obtained for c
carbamylcholine (CCh), cytosine (Cyt), nicotine (Nic) and epibatidine (Epi). Lines represe
n): CCh ch1 (5.0, 260, 2.3), CCh mutant (0.3, 1890, 1.3); Cyt ch1 (7.3, 30, 2.1), Cyt mutant
1.2), and Epi mutant (8.4, 7.9, 1.9). All currents were measured at 40 mV, except for t
smaller size.
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As occurred in the mutation made on a7 wild type receptors, this
change in the EC50 value is not quantitatively predicted by consid-
ering only the modiﬁcation in gating [13]. Thus, a change in the
ACh binding properties is likely to have taken place as well.
3.2. Pharmacological proﬁle
Mutations of Lys145 in a7 wild type receptors induced changes
in the pharmacological proﬁle of the resultant receptors [2]. There-
fore, we checked the functional responses of ch1 and mutant ch1/
K145A receptors to several nicotinic drugs. All agonists tested
evoked ionic currents that were kinetically indistinguishable from
ACh-evoked currents both in ch1 and in mutant ch1/K145A recep-
tors (not shown).
Fig. 2 shows representative concentration-current relationships
for carbamylcholine, cytisine, nicotine and epibatidine. When com-
pared to ch1 curves, those obtained with mutant ch1/K145A were
consistently shifted to the right, showing statistically signiﬁcant
higher EC50 values, and all, except epibatidine, showed a large
reduction in the maximal current (note that ch1 currents in
Fig. 2 were measured at 40 mV while mutant currents obtained
with CCh, Cyt and Nic were measured at 80 mV because of their
smaller size).
We did the same analysis for each individual oocyte, selecting
only those for which it was possible to obtain the whole current–
concentration curve, and averaged the resulting ﬁtting parameters.
The results are summarized in Table 1 in supplementary data. The
differences in EC50 were statistically signiﬁcant for all the agonists
tested. The main differences in EC50 were observed in ACh, cytisine
and nicotine where the mutation produced a shift of approxi-
mately 50-, 40- and 30-fold, respectively, whereas the shift was
only 7- and 6-fold for carbamylcholine and epibatidine, respec-0 1 2 3 4
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h1 (open circles) and mutant receptors (ﬁlled circles) for four different agonists:
nt ﬁts of data to the Hill equation with the following parameters (Imax/lA, EC50/lM,
(1.1, 490, 1.8); Nic ch1 (11.4, 64, 3.3), Nic mutant (1.8, 2090, 1.7); Epi ch1 (9.1, 2.2,
he mutants with CCh, Cyt and Nic that were measured at 80 mV because of their
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also signiﬁcant, except for epibatidine, and their magnitude was
not correlated with the shift in EC50. Thus, the reductions in Imax
were small (about 5-fold) for ACh, nicotine and cytisine, and was
greater for carbamylcholine (almost 25-fold).
The large reduction in Imax for carbamylcholine was not as great
as reported in a7/K145 where this agonist became a competitive
antagonist. However, as happened with a7/K145A, that change
from agonist to antagonist was in fact observed here for ch1/
K145A with DMPP. In ch1 receptors, DMPP evoked currents similar
to the other agonists; its concentration-current curve was very
similar to that of cytisine ant its potency was only inferior to that
of epibatidine. In contrast, we were unable to detect any currents
when DMPP was applied to ch1/K145A receptors. The effect of
DMPP on ch1/K145A receptors was similar to other competitive
nicotinic antagonists as methyllycaconitine (MLA), as shown in
Fig. 3. In ch1/K145A mutant receptors, DMPP was able to inhibit
the currents elicited by 10 mM ACh with an IC50 of 80 lM approx-
imately, a value almost 30 times larger than that of MLA. For nic-
otinic antagonist MLA the mutation ch1/K145A gave as a result a
signiﬁcant shift in IC50 towards smaller concentrations by approx-
imately a factor of 4. The corresponding values of the afﬁnity con-
stant for the inhibition, Ki, were: 35 lM for DMPP on ch1/K145A
and only 0.8 lM and 1.2 lM for MLA on ch1 and ch1/K145A,
respectively. The difference between these last two values was
not statistically signiﬁcant. Similar results were obtained for
dihydro-b-erythroidin (DHbE), data not shown.-1 0 1 2 3 4
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Fig. 3. Pharmacological proﬁle: antagonists. Normalized activation and inhibition
curves. For each individual oocyte activation or inhibition data (i.e. current–
concentration curves) were ﬁtted to the Hill equation and the resulting Imax was
used to normalize the values of the current. The data points in the ﬁgures show the
averaged values and standard errors of the normalized values. The lines are ﬁts to
the Hill equation of the resulting averages for ch1 (open circles, dotted lines) and
the mutant ch1/K145A (solid circles and lines), for DMPP (panel A) and for the
antagonist methyllycaconitine (MLA) (panel B). Inhibition curves were obtained by
co-applying the different antagonist concentrations with 1 mM ACh for ch1 or
10 mM ACh for ch1/K145A with a Hill coefﬁcient of 1. Fit parameters are
summarized in Table 1 in supplementary data.3.3. Unitary currents in ch1 and ch1/K145A
So far as macroscopic currents are concerned, substitution of
Lys145 by alanine showed the same effects in ch1 than in wild type
a7 receptors. However, we could study the role of Lys145 in more
detail in ch1 than in wild type a7 receptors because the slowly
desensitizing properties of ch1 allowed acquiring single-channel
recordings in the cell-attached conﬁguration of the patch-clamp
technique.
Fig. 4 shows typical cell-attached single-channel recordings at
different concentrations of ACh in ch1 and ch1/K145A receptors.
For each receptor, three different concentrations are shown. Those
concentrations have been chosen, according to the macroscopic
current–concentration curves, corresponding to the steep part of
the curve and are roughly equipotent for each receptor.
In both receptors the open probability was higher in those
patches with higher ACh concentration. This can be seen from
the relative area of the second peak in the all points histograms,
that correspond to the openings of the channel. The overall open
probability was small as can be inferred by the large relative mag-
nitude of the baseline peak compared with the second peak. In the
ﬁgure, the largest open probability corresponds to the patch with
ch1 receptors with ACh 100 lM, and it was approximately 10%.
As can be seen in Fig. 4, the magnitude of the currents at
100 mV was usually larger in ch1 (about 7.5 pA) than in ch1/
K145A (5 pA approximately), this difference is probably a conse-
quence of agonist block as the conductance of the channel de-
creased with increasing concentration, although not in a linear
manner (see bottom of Fig. 4). The single-channel conductance
measured between 20 and 120 mV with different ACh concen-
trations ranged between 86 ± 5 pS at 10 lM, and 50 ± 2 pS at
10 mM for ch1; and between 77 ± 13 pS at 3 mM, and 16 ± 3 pS
at 30 mM for ch1/K145A. No different conductance levels were ob-
served in a given patch. The extrapolated value for the reversal po-
tential was close to 0 mV for both receptors.
In Fig. 4, the duration of the openings was also larger in ch1
than in ch1/K145A at the corresponding concentration, and a more
detailed analysis is presented in the following section.
3.4. Single-channel kinetics in ch1 and ch1/K145A
Mutant ch1/K145A has shorter openings than ch1. Fig. 5 shows
typical records of 200 ms duration with openings for ch1 and ch1/
K145A for four different agonists. The agonist concentrations used
were 100 lM for ch1 and 1 mM for ch1/K145A in all cases except
for epibatidine in which 10 lM was used for both receptors. The
data in recordings of 5 min were idealized by the half amplitude
method and divided into segments with clusters of activity deﬁned
by having a closed time longer than a given burst terminator time,
between 30 and 100 ms depending on the activity of the channel.
Bursts with more than one open level, indicating the activity of
multiple channels, were discarded. The resulting dwell time histo-
grams are shown in Fig. 5 at the right of the records. The histo-
grams were ﬁtted to the kinetic model given in the methods
section and the averaged values of the ﬁtted parameters for differ-
ent number of patches are shown in Table 2 in supplementary data.
For the time constants the data show that comparing a given
receptor with different agonists, and taking ACh as our reference,
the only statistically signiﬁcant differences were for the longer
open time constant (so2): with Cytisine it was four times smaller,
whereas with Epi it was approximately three times larger. On the
other hand when the dwell times for ch1 were compared with
those for ch1/K145A, for each agonist, the statistically signiﬁcant
differences indicated that the mutant receptor had usually longer
closed times and especially that the duration of the longer open-
ings was reduced by approximately 5-fold. These results suggest
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Fig. 4. Single-channel recordings with ACh. (A) Representative traces of single-channel currents evoked by ACh in ch1 (left) and mutant ch1/K145A receptors (right) at
different concentrations. Openings are downward. For each agonist concentration, a record of 1 s duration is shown. The region of each record marked with an asterisk is
shown below at a 10-fold expanded time resolution. The histograms at the right of each record are all points histograms created from 5 min long recordings, normalized to
have a total area of one. The scale is the same in all histograms, and the ﬁrst peak (out of scale) corresponds to the baseline level. (B) Single-channel conductance as a function
of agonist concentration for ch1 (open dots) and ch1/K145A mutant receptors (solid dots).
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nel activation and destabilization of the open conﬁguration.
In terms of the kinetic constants of the model used to analyze
the data, the main differences seen with the mutant ch1/K145A
that are reproduced for all agonists were with the kinetic constants
b2 and a2. The opening rate constant b2 is reduced in the mutant by
a factor between 3 (in the case of ACh) and 10 (for epibatidine). On
the other hand, the closing rate constant a2, that determines the
mean dwell time of the open state with longer duration, is in-
creased by the mutation by a factor of between 2 and 10 (for epib-
atine and nicotine, respectively), thus making the transition from
the open to the closed state faster in that factor. Both changes sug-
gest again that in ch1 receptors the mutation K145A impairs the
channel activation and destabilizes the conﬁguration of one of
the open states.
4. Discussion
The mutation K145A in chimeric receptors ch1 had very similar
effects to those observed in wild type a7 receptors at macroscopic
level [2], i.e. the maximal current obtained with ACh decreased and
the current–concentration curve was shifted towards higher con-centrations by almost two orders of magnitude. Such large shift
cannot be quantitatively explained by a simple reduction in gating
[13]. The number of receptors present in the surface of the oocytes,
as determined by a-Bgt binding experiments was not affected by
the mutation whereas a small reduction of about 25% was observed
when the same mutation was introduced in a7 receptors.
The pharmacological proﬁle of the mutated ch1/K145A recep-
tors was also very similar to its counterpart in a7 receptor.
Lys145 affects the effectiveness of ACh, CCh, nicotine, cytisine
and DMPP. The main effect being the conversion of DMPP from
agonist to competitive antagonist. Moreover, as in a7 receptors,
epibatidine was the less affected agonist. Competitive nicotinic
antagonists also seemed to change their properties in mutant
ch1/K145A receptors as revealed by the shifts in the inhibition
curves of the a7-selective antagonist MLA. Again this effect is sim-
ilar to the one observed in mutated a7 receptors, however, the
quantitative details are different. In a7 the mutation produces an
increase in the potency of the antagonist, as revealed by a decrease
in the afﬁnity constant Ki by a factor of 6, whereas in ch1 mutants
the change in Ki was not signiﬁcant. The contributions of residues
of the extracellular domain to the pharmacological proﬁle of the
nicotinic receptor has been reported previously [14–17] and thus
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Fig. 5. Dwell time histograms of single-channel events. Sample single-channel recordings with openings and histograms for closed (tc), and open (to) time for ch1 (left) and
mutant ch1/K145A (right) receptors with different agonists: acetylcholine, cytisine, nicotine and epibatidine. All the records are of 200 ms duration and shown at the same
scale. The dwell time histograms were obtained from records of 5 min duration. Logarithmic binning and linear scale for relative frequency of events were used. The analysis
was restricted to bursts of activity usually limited by closed times shorter than 100 ms, or 30 ms in cases of patches with more than one channel and large activity.
Superimposed to the histograms are the ﬁts, in dotted lines, to kinetic Scheme 1.
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mination of the pharmacological proﬁle of nicotinic receptors.
The experimental model ch1 was used not only because it
reproduced the effect of mutations on residue Lys145 on the mac-
roscopic currents and pharmacological proﬁle of wild type a7
receptors but also because it allowed us to study the function of
the receptor at the single-channel level as the mutation of the argi-
nines in the intracellular domain result in a channel with an in-
creased conductance that makes it easy to measure [7]. Although
we could not obtain stable outside-out patches to perform concen-
tration jump experiments with agonists in order to investigate the
microscopic mechanism of the channel function, we were able to
obtain long duration recordings in the cell-attached conﬁguration
and the observed activity of the channel increased with ACh con-
centration in both ch1 and ch1/K145A receptors. The measured
single-channel conductance of the mutated receptor was smaller
than that of ch1, probably due to the fact that large concentrations
of agonist have a blocking effect on the pore as reported [18]. This
reduction in single-channel conductance, however, is not enough
to account quantitatively for the reduction in function observed
in the mutated receptors, thus a change in the kinetics of the recep-
tor was also expected.
The kinetic analysis of single-channel recordings was compli-
cated by the fact that many of the patches that we recorded hadmore than one channel present, so that closed times could not be
attributed to a single receptor, instead we limited our analysis to
bursts of activity with no overlapping openings. The activity of
the patches was usually smaller in the mutated receptors so that
bursts could be delimited by longer closed times. The longer closed
times we used were 100 ms but in some patches with ch1 recep-
tors and ACh we had to reduce this value to 30 ms due to a much
larger activity. This change, however, did not produce statistical
outliers when the results were analyzed for a given pair of receptor
and agonist.
For agonists tested the mutated receptor had shorter open
times and usually longer closed times than ch1 receptor. As previ-
ously reported [18], we also observed an open time distribution
with two distinct time constants and both were reduced in the mu-
tant receptor, but mainly the longer one (despite the fact that the
higher concentrations used for the mutant can produce open
channel block and therefore lengthen the open interval durations
[19]), thus indicating that there is an increase in the values of
the kinetic constants a1 and a2 that close the channel. There was
also a change in the closed time distributions but the correspond-
ing kinetic constant affected cannot be attributed to a single
property of the closed dwell time distribution.
These results are in qualitative agreement with those obtained
in muscle nAChRs showing that substitution of Ala for Lys145 in-
J.A. Bernal et al. / FEBS Letters 583 (2009) 1045–1051 1051tensely affected receptor activation but mostly by a large reduction
in opening rate constant [3,4], and also in neuronal nicotinic recep-
tors as observed in our recent study on bovine a7 mutant receptors
K145A-L248T that have impaired gating as a consequence of a
slower opening rate constant [5]. Thus, our data also suggest that
Lys145 is involved in the early steps of nAChR activation, and this
would be expected given its location in the structure of the recep-
tor [20], but also that Lys145 may play a role in stabilizing the open
conﬁguration of the channel. Quantitative discrepancies between
muscle- and neuronal type nAChR gating have been reported pre-
viously [2,9,21,22].
Although we have used a chimeric receptor for studying the role
of K145 in the gating mechanism of nicotinic receptors we think
that our results can be extrapolated to the wild type receptor as
we have shown that the pharmacological proﬁle of the receptor
is conserved and that the macroscopic effects of the mutation
Lys145A are the same. The possibility of obtaining long duration
single-channel recordings has enabled us to study the mechanism
in more detail and to show that Lys145 is involved in the process of
channel activation and stabilization of the open conﬁguration of
the neuronal nicotinic receptors.
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